Platinum- vs nonplatinum-based therapy in NSCLC

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1496, 2005-01, pp. : 13-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Platinum- and non-platinum-based regimens compared in NSCLC

By  

Inpharma, Vol. 1, Iss. 1288, 2001-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Pharmacogenomics of platinum-based chemotherapy in NSCLC

By Hildebrandt Michelle AT   Gu Jian   Wu Xifeng  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 7, 2009-07 ,pp. : 745-755

Informa Healthcare

Access to resources Recommend Favorite

Gemcitabine + vinorelbine: superior to platinum-based regimens in NSCLC?

By  

Inpharma, Vol. 1, Iss. 1308, 2001-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Cisplatin-based adjuvant therapy improves survival in NSCLC

By  

Inpharma, Vol. 1, Iss. 1422, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Influence of polymorphisms in MTHFR 677 C→→T, TYMS 3R→→2R and MTR 2756 A→→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC

By Cui Lian-Hua   Yu Zhuang   Zhang Ting-Ting   Shin Min-Ho   Kim Hee-Nam   Choi Jin-Su  

Pharmacogenomics, Vol. 12, Iss. 6, 2011-06 ,pp. : 797-808

Future Medicine

Access to resources Recommend Favorite